Haizheng pharmaceutical's third generation insulin recombinant insulin glargine injection has been approved successfully

According to the information on CFDA website, the status of the third generation insulin recombinant insulin glargine injection declared by Haizheng Pharmaceutical (600267 SH) for clinical application has changed to "certificate preparation completed - issued approval document", and the drug may have been approved for clinical application successfully In response, the Securities Department of the company did not respond, saying it had not received the notice Haizheng pharmaceutical has been distributing insulin products since 2009 Up to now, it has distributed five varieties in this field, all of which are for clinical application, including 30 / 70 mixed recombinant human insulin injection, recombinant human insulin injection, recombinant human insulin injection, recombinant insulin glargine injection and recombinant insulin asparagus injection The first three varieties are two The last two varieties were the third generation insulin At present, the second-generation insulin market in China has been mature, and the relevant varieties have been produced by many enterprises, with fierce competition In contrast, three generations of insulin products are rare in China, among which, insulin glargine is only produced by Sanofi, the original research pharmaceutical enterprise, and Ganli pharmaceutical, the domestic pharmaceutical enterprise; while insulin asparagus is only sold by Novo Nordisk's imported drugs Haizheng pharmaceutical is a leading API manufacturer in China, and one of the largest production bases of antibiotics and anti-tumor drugs in China At present, it is in the stage of transformation from API to preparation In 2013, the profit of Haizheng pharmaceutical preparation business exceeded that of API for the first time, and the transformation has achieved initial results.